Avoiding systemic estrogen does not leave only one way to address bothersome hot flashes. Several prescription approaches and some structured non-drug treatments have supporting evidence. They differ in how they work, the outcomes studied and the precautions that matter. Calling them all nonhormonal can conceal those differences just when a reader needs them explained.
This guide organizes the treatment families without choosing one for you. It also separates a medicine's approved indication from other clinician-directed uses and places newer approvals alongside older evidence reviews. A useful discussion starts with the symptom you want help with, then considers the exact treatment and medical history rather than treating nonhormonal as a general safety endorsement.
Begin with the hot-flash goal, not every symptom of menopause
Hot flashes and night sweats are often grouped as vasomotor symptoms, or VMS. The Menopause Society's patient explanation describes how disruptive they can be and discusses treatment options. Reducing their frequency, severity or effect on daily life is a specific treatment goal. It is not the same as treating every cause of poor sleep, low mood, vaginal discomfort or fatigue.
Tell the clinician which problem is most disruptive and whether other symptoms need separate assessment. A medicine studied for hot flashes should not acquire an all-purpose menopause claim because several symptoms occur together. Our visit-goals guide helps make those priorities clear. It does not ask you to identify a diagnosis or determine from a symptom list which prescription you should receive.
Selected SSRIs and SNRIs have evidence for vasomotor symptoms
SSRIs and SNRIs are medicine families that affect serotonin, or serotonin and norepinephrine, signaling. Selected medicines in these families have hot-flash evidence in the 2023 nonhormone position statement. Their appearance in a menopause discussion does not, by itself, mean a clinician has diagnosed depression. It also does not establish that every antidepressant has the same evidence for this purpose.
Approval is product-specific. Brisdelle is a 7.5 mg paroxetine capsule approved for moderate-to-severe VMS due to menopause. CoreAge's page advertises oral paroxetine 10 mg and explicitly describes its menopause use as off-label. These strengths identify different product claims, not choices or doses recommended here. Our CoreAge review preserves that distinction rather than borrowing Brisdelle's approval.
Neurokinin-targeted medicines are a separate family
Veozah's current label identifies fezolinetant as a neurokinin 3, or NK3, receptor antagonist. Lynkuet's label identifies elinzanetant as an antagonist at NK1 and NK3 receptors. These medicines act on signaling involved in temperature regulation; they are not estrogen replacement and should not be described as interchangeable versions of the same product.
Two receptor targets do not prove greater clinical benefit than one. Nor does a shared NK3 target give the medicines identical precautions. Veozah has a boxed liver warning; Lynkuet has its own liver-testing requirements and additional nervous-system precautions. The fezolinetant guide and elinzanetant evidence guide examine those separate records. A mechanism explains a treatment approach, while clinical trials and labeling establish its practical evidence and limits.
Other prescription options need their own evidence and tolerability review
The 2023 position statement also supports gabapentin and oxybutynin as nonhormonal options, with different evidence assessments. Their inclusion does not make them FDA-approved specifically for hot flashes, and it does not mean they have the same adverse effects or interaction considerations as the medicines above. An evidence-supported clinical use and an approved indication are separate questions.
Ask why the clinician is discussing a particular medicine and which daily-life concerns affect the choice. Existing prescriptions, alertness, other health conditions and previous adverse effects can matter. This article gives no starting regimen, combination or substitution. The FDA's off-label explanation clarifies how clinicians may consider an approved medicine for an unapproved use without implying that FDA has approved that additional use.
Non-drug support belongs in the evidence discussion
Cognitive behavioral therapy and clinical hypnosis are supported options in the 2023 evidence review. They are structured interventions, not a claim that hot flashes are imaginary or that a person should simply tolerate them. Their research concerns outcomes such as symptom burden and, depending on the intervention, hot-flash measures. Ask what program is being offered and what benefit its evidence actually measures.
Do not group those interventions together with every product sold as natural. The same statement does not recommend supplements and herbal remedies as effective VMS treatments. Comfort measures may still feel helpful, but a personal preference and demonstrated treatment efficacy are different claims. A care discussion can include a supported non-drug approach without turning it into a promise of complete relief or a substitute for assessment.
Nonhormonal does not remove medication-specific precautions
A cancer history or a preference to avoid estrogen is a reason to discuss alternatives, not automatic clearance for every alternative. Brisdelle's label warns that paroxetine may reduce tamoxifen's effectiveness and identifies other important interactions. Anyone receiving cancer-related care needs the prescribing teams to review the actual medicines together; this guide does not direct a change to either treatment.
Other products raise different questions. Lynkuet's August 2026 label includes daytime impairment, liver-enzyme monitoring and a seizure-risk warning. Veozah's liver precautions are discussed separately. A treatment can have evidence of benefit while still being unsuitable for a particular person. The consultation should explain those individual considerations instead of treating the absence of estrogen as the end of the safety discussion.
Read older overviews with the approval timeline in mind
The 2023 position statement remains useful for the treatments it evaluated, but it predates the October 2025 FDA approval of Lynkuet. A current overview needs both the older evidence and later product records. It should not suggest that an option lacks approval merely because it was absent from an earlier statement.
Our care comparison examines service questions without making these treatment families into a shopping ranking. Another Way Through belongs to the CoreAge Rx promotional publishing network, explaining CoreAge's first commercial placement. That position is not a clinical preference among medicines. A useful next step is an explained treatment discussion that names the goal, evidence, precautions and follow-up responsibilities for the actual proposal.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- The Menopause Society: Hot FlashesMedical society patient information · Checked 2026-09-27
- The Menopause Society: 2023 nonhormone therapy position statementMedical society evidence review · Checked 2026-09-27
- DailyMed: Brisdelle paroxetine capsules, updated April 28, 2025Exact product labeling · Checked 2026-09-27
- CoreAge Rx: Non-Hormonal Menopause, oral paroxetine offerProvider product information · Checked 2026-09-27
- DailyMed: Veozah prescribing information, updated February 26, 2026Exact product labeling · Checked 2026-09-27
- Bayer: Lynkuet US prescribing information, revised August 2026Current US prescription product labeling · Checked 2026-09-27
- FDA: Understanding unapproved use of approved drugsRegulator explanation · Checked 2026-09-27
- FDA: Lynkuet drug trials snapshot, approved October 24, 2025Regulator approval and trial summary · Checked 2026-09-27